Clinical Trial Update: A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating single and multiple doses of KHK6640 in participants with prodromal or mild to moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• KHK6640

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED